How Should We View the Results of the Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1)?

por Ross, Merrick I., Gershenwald, Jeffrey E.
Publicado 2008

Bilateral Breast Reconstruction With Profunda Artery Perforator Flaps and Immediate Implant Augmentation

por Chu, Carrie K, DeFazio, Michael, Largo, Rene D, Ross, Merrick
Publicado 2020

The Great Debate at “Melanoma Bridge”, Napoli, December 2nd, 2017

por Ascierto, Paolo A., Caracò, Corrado, Gershenwald, Jeffrey E., Hamid, Omid, Ross, Merrick, Sullivan, Ryan J., Puzanov, Igor
Publicado 2018

Metastatic melanoma to the testis

por Patnana, Madhavi, Korivi, Brinda Rao, Devine, Catherine E, Faria, Silvana, Prieto, Victor, Ross, Merrick I., Ng, Chaan S.
Publicado 2018

Association between durable response (DR) and overall survival (OS) in patients with unresected stage IIIb-IV melanoma treated with Talimogene Laherparepvec (T-VEC) in the Phase II...

por Kaufman, Howard L, Andtbacka, Robert HI, Collichio, Frances A, Wolf, Michael, Li, Ai, Shilkrut, Mark, Puzanov, Igor, Ross, Merrick
Publicado 2014

Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials

por Kaufman, Howard L., Andtbacka, Robert H. I., Collichio, Frances A., Wolf, Michael, Zhao, Zhongyun, Shilkrut, Mark, Puzanov, Igor, Ross, Merrick
Publicado 2017

Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma

por Eton, Omar, Ross, Merrick I, East, Mary Jo, Mansfield, Paul F, Papadopoulos, Nicholas, Ellerhorst, Julie A, Bedikian, Agop Y, Lee, Jeffrey E
Publicado 2010

Fibrin sealant does not decrease seroma output or time to drain removal following inguino-femoral lymph node dissection in melanoma patients: A randomized controlled trial (NCT0050...

por Mortenson, Melinda M, Xing, Yan, Weaver, Storm, Lee, Jeffrey E, Gershenwald, Jeffrey E, Lucci, Anthony, Mansfield, Paul F, Ross, Merrick I, Cormier, Janice N
Publicado 2008

Presence of Circulating Tumor Cells Predates Imaging Detection of Relapse in Patients with Stage III Melanoma

por Lucci, Anthony, Addanki, Sridevi, Chiang, Yi-Ju, Meas, Salyna, Sarli, Vanessa N., Upshaw, Joshua R., Manchem, Mayank, Patel, Sapna P., Wargo, Jennifer A., Gershenwald, Jeffrey E., Ross, Merrick I.
Publicado 2023

Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma

por Thompson, John F., Agarwala, Sanjiv S., Smithers, B. Mark, Ross, Merrick I., Scoggins, Charles R., Coventry, Brendon J., Neuhaus, Susan J., Minor, David R., Singer, Jamie M., Wachter, Eric A.
Publicado 2014

Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial

por Andtbacka, Robert H. I., Ross, Merrick, Puzanov, Igor, Milhem, Mohammed, Collichio, Frances, Delman, Keith A., Amatruda, Thomas, Zager, Jonathan S., Cranmer, Lee, Hsueh, Eddy, Chen, Lisa, Shilkrut, Mark, Kaufman, Howard L.
Publicado 2016

Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte‐macrophage colony‐stimulating factor for the treatment of unres...

por Andtbacka, Robert H. I., Agarwala, Sanjiv S., Ollila, David W., Hallmeyer, Sigrun, Milhem, Mohammed, Amatruda, Thomas, Nemunaitis, John J., Harrington, Kevin J., Chen, Lisa, Shilkrut, Mark, Ross, Merrick, Kaufman, Howard L.
Publicado 2016

Impact of the 2009 (7th Edition) AJCC Melanoma Staging System in the Classification of Thin Cutaneous Melanomas

por Chu, Vicki H., Tetzlaff, Michael T., Torres-Cabala, Carlos A., Prieto, Victor G., Bassett, Roland, Gershenwald, Jeffrey E., McLemore, Michael S., Ivan, Doina, Wang, Wei-Lien (Billy), Ross, Merrick I., Curry, Jonathan L.
Publicado 2013

A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer

por Kai, Megumi, Marx, Angela N., Liu, Diane D., Shen, Yu, Gao, Hui, Reuben, James M., Whitman, Gary, Krishnamurthy, Savitri, Ross, Merrick I., Litton, Jennifer K., Lim, Bora, Ibrahim, Nuhad, Kogawa, Takahiro, Ueno, Naoto T.
Publicado 2021

Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma

por Andtbacka, Robert H.I., Wang, Yan, Pierce, Robert H., Campbell, Jean S., Yushak, Melinda, Milhem, Mohammed, Ross, Merrick, Niland, Katie, Arbeit, Robert D., Parasuraman, Sudha, Bickley, Kris, Yeung, Cecilia CS, Aicher, Lauri D., Smythe, Kimberly S., Gan, Lu
Publicado 2022

Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II tria...

por Chesney, Jason A, Puzanov, Igor, Collichio, Frances A, Singh, Parminder, Milhem, Mohammed M, Glaspy, John, Hamid, Omid, Ross, Merrick, Friedlander, Philip, Garbe, Claus, Logan, Theodore, Hauschild, Axel, Lebbé, Celeste, Joshi, Harshada, Snyder, Wendy, Mehnert, Janice M
Publicado 2023

Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma

por Ribas, Antoni, Camacho, Luis H, Lee, Sun Min, Hersh, Evan M, Brown, Charles K, Richards, Jon M, Rodriguez, Maria Jovie, Prieto, Victor G, Glaspy, John A, Oseguera, Denise K, Hernandez, Jackie, Villanueva, Arturo, Chmielowski, Bartosz, Mitsky, Peggie, Bercovici, Nadège, Wasserman, Ernesto, Landais, Didier, Ross, Merrick I
Publicado 2010

Association of Common Genetic Polymorphisms with Melanoma Patient IL-12p40 Blood Levels, Risk, and Outcomes

por Fang, Shenying, Wang, Yuling, Chun, Yun S, Liu, Huey, Ross, Merrick I, Gershenwald, Jeffrey E, Cormier, Janice N, Royal, Richard E, Lucci, Anthony, Schacherer, Christopher W, Reveille, John D, Chen, Wei, Sui, Dawen, Bassett, Roland L, Wang, Li-E, Wei, Qingyi, Amos, Christopher I, Lee, Jeffrey E
Publicado 2015

Identification of MicroRNA–mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes

por Sloane, Robert A. Szczepaniak, White, Michael G., Witt, Russell G., Banerjee, Anik, Davies, Michael A., Han, Guangchun, Burton, Elizabeth, Ajami, Nadim, Simon, Julie M., Bernatchez, Chantale, Haydu, Lauren E., Tawbi, Hussein A., Gershenwald, Jeffrey E., Keung, Emily, Ross, Merrick, McQuade, Jennifer, Amaria, Rodabe N., Wani, Khalida, Lazar, Alexander J., Woodman, Scott E., Wang, Linghua, Andrews, Miles C., Wargo, Jennifer A.
Publicado 2021

Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma

por Ho, Joel, Mattei, Jane, Tetzlaff, Michael, Williams, Michelle D., Davies, Michael A., Diab, Adi, Oliva, Isabella C. Glitza, McQuade, Jennifer, Patel, Sapna P., Tawbi, Hussein, Wong, Michael K., Fisher, Sarah B., Hanna, Ehab, Keung, Emily Z., Ross, Merrick, Weiser, Roi, Su, Shirley Y., Frumovitz, Michael, Meyer, Larissa A., Jazaeri, Amir, Pettaway, Curtis A., Guadagnolo, B. Ashleigh, Bishop, Andrew J., Mitra, Devarati, Farooqi, Ahsan, Bassett, Roland, Faria, Silvana, Nagarajan, Priyadharsini, Amaria, Rodabe N.
Publicado 2022